Direct-to-Phase II SBIR Grant from NIH Awarded to Neurexis Therapeutics to Evaluate Neuroprotective Therapeutic in Stroke Preclinical Assessment Network (SPAN)

A promising approach for preventing cognitive and behavioral impairment following ischemia Aurora, CO - Neurexis Therapeutics, Incorporated, announces it has been awarded $900,000 in funding from a Direct-to-Phase II...

Solaris Vaccines Adds Izabela Ragan as Director of Research and Development for the SolaVAX™ Platform

FORT COLLINS, CO – Solaris Vaccines, Inc. announced today that Dr. Izabela Ragan (DVM, PhD), an expert in novel vaccine technologies, has joined as Director of Research and Development. The Company is developing a...

Intellectual Property Landscape Analysis Using Free Patent Databases

For an investor seeking a decision on whether or not to invest in an innovation-based startup, there are numerous factors they need to take into consideration. Some of the most important questions that need to be...

Due Diligence for Life Science Investments

Investing in a life science startup can be a lucrative opportunity, but it requires careful evaluation to weigh the potential reward against the level of risk. Members of VIC Tech's affiliated VIC Investor Network...

From the Corner Office: Michael Artinger, PhD – CEO of Solaris Vaccines, Inc.

I have been very fortunate to have had a varied and diverse career accelerating the development of life science innovation, including therapeutics, vaccines, medical devices, diagnostics, analytical instruments,...

Cellia Science Awarded National Institutes of Health Phase I SBIR Funding

Fayetteville, AR - Cellia Science, a point-of-care hematology company, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Heart, Lung, and Blood...

VIC Fellows Spotlight: Matthew Leming, PhD

The VIC Fellows Program provides an opportunity for individuals with relevant expertise and interest to learn how to identify and evaluate promising innovations from global sources. We are pleased to highlight the...

VIC 2022 Annual Report Executive Summary

2022 was a highly productive year for VIC and our portfolio companies. Click Here to download the Annual Report Executive Summary or view it below.

VIC Tech Adds Chantell Preston to Board of Directors

Bringing a proven track record in healthcare operations, innovation, and investing. FAYETTEVILLE, AR- VIC Technology Venture Development is pleased to announce the appointment of Chantell Preston, who brings 20+ years...

A Letter from our CEO

As CEO of VIC Tech, I am fortunate to have the opportunity to review exciting new life science technologies on an ongoing basis and regularly speak with life science thought leaders, inventors, investors, and large...

FEATURED RESOURCES

Updates
VIC Tech Announces New Class of Fellows
Insight
Our Life Science and Healthcare Future
White Paper
Portfolio Diversification in Times of Market Volatility
Interview
Inside the Office of Technology Commercialization at the University of Kentucky with Holly Clark, PhD, Senior Commercialization Manager
Insight
Seven Reasons Venture Capital-Stage Companies Should Become Part of Your Investment Portfolio
White Paper
Investing in Medical Devices & Diagnostics – Industry Trends and Investor Activity
News
Nob Hill Therapeutics Secures Series A Funding to Advance Breakthrough Respiratory Technologies
Interview
VIC Fellows Spotlight: Matthew Leming, PhD
From The Corner Office
From the Corner Office: Zebra Analytix